Wall Street Zen Upgrades X4 Pharmaceuticals (NASDAQ:XFOR) to Hold

X4 Pharmaceuticals (NASDAQ:XFOR) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other equities analysts have also issued reports on XFOR. Zacks Research lowered X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 26th. Weiss Ratings restated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a report on Monday, December 29th. Stifel Nicolaus set a $10.00 target price on X4 Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, December 5th. Finally, Guggenheim started coverage on X4 Pharmaceuticals in a report on Monday, March 9th. They set a “buy” rating and a $12.00 target price on the stock. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, X4 Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.88.

X4 Pharmaceuticals Trading Up 2.6%

NASDAQ:XFOR opened at $4.28 on Friday. X4 Pharmaceuticals has a 1 year low of $1.35 and a 1 year high of $9.56. The stock has a market cap of $389.14 million, a price-to-earnings ratio of -0.99 and a beta of 0.43. The business has a fifty day moving average of $3.67 and a 200-day moving average of $3.63. The company has a debt-to-equity ratio of 0.41, a quick ratio of 9.98 and a current ratio of 10.16.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.14. The business had revenue of $2.57 million for the quarter, compared to analysts’ expectations of $1.68 million. X4 Pharmaceuticals had a negative net margin of 225.55% and a negative return on equity of 115.27%. Equities analysts predict that X4 Pharmaceuticals will post -0.68 earnings per share for the current year.

Institutional Trading of X4 Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Indivisible Partners acquired a new position in shares of X4 Pharmaceuticals in the fourth quarter worth about $40,000. Squarepoint Ops LLC acquired a new stake in shares of X4 Pharmaceuticals during the fourth quarter valued at approximately $50,000. Two Sigma Investments LP acquired a new stake in shares of X4 Pharmaceuticals during the third quarter valued at approximately $47,000. Stifel Financial Corp purchased a new stake in shares of X4 Pharmaceuticals in the 4th quarter valued at approximately $82,000. Finally, Virtu Financial LLC acquired a new position in X4 Pharmaceuticals in the 4th quarter worth approximately $90,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals News Roundup

Here are the key news stories impacting X4 Pharmaceuticals this week:

• Positive Sentiment: Brookline materially improved its FY2026 EPS view (from -$1.50 to -$1.04), a smaller near‑term loss that suggests a faster path toward profitability. Brookline Cap M FY2026 estimate
• Positive Sentiment: Brookline raised its FY2027 EPS forecast (from -$1.70 to -$0.96), reducing multi‑year downside and improving the medium‑term outlook. Brookline Cap M FY2027 estimate
• Positive Sentiment: Brookline lifted its FY2028 estimate (from -$0.42 to -$0.24), another sign of improving expected margins in later years. Brookline Cap M FY2028 estimate
• Positive Sentiment: Brookline published a long‑range FY2030 EPS projection of $2.85, signaling significant upside potential if X4 hits longer‑term commercialization and scaling assumptions. Brookline Cap M FY2030 estimate
• Neutral Sentiment: Brookline provided updated quarterly EPS forecasts for 2026 (Q1: -$0.20, Q2: -$0.23, Q3: -$0.27, Q4: -$0.34) that set expectations for near‑term performance but are routine analyst guidance updates rather than company‑driven news. Brookline Cap M quarterly estimates
• Negative Sentiment: Brookline cut its FY2029 EPS forecast sharply (from $1.52 to $0.85), lowering medium‑term upside and indicating the analyst reduced confidence in the timing/scale of revenue or margin improvements for that year. Brookline Cap M FY2029 revision

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.